Animal genetics firm Genus led the charge in London as the FTSE 100 clocked up a thirteenth day of gains despite a slump in the US economy.
Shares in FTSE 250-listed Genus jumped 16.1 per cent, or 256p, to 1842p after a key product won approval from the US Food and Drug Administration.
The wider market was also on the move with the FTSE 100 up 0.4 per cent, or 31.39 points, to 8494.85 and the FTSE 250 gained 0.4 per cent, or 74.87 points, to 19884.59.
The blue-chip index has risen for 13 days in a row, with the latest rise coming despite the US economy shrinking at an annual rate of 0.3 per cent in the first quarter.
Hip replacement maker Smith & Nephew jumped 5.8 per cent, or 58p, to 1054p as a better-than-expected 3.1 per cent rise in first quarter revenues offset a tariff hit of up to £15million.
But miner Glencore fell 7.4 per cent, or 19.5p, to 244.4p after reporting a 30 per cent drop in first quarter copper production.
Taylor Wimpey expects lower profit margins in the first half of 2025, amid lower selling prices and rising inflation for builders. Shares lost 0.8 per cent, or 1p, to 117.45p.
Gene therapy: Shares in FTSE 250-listed Genus jumped 16.1% after a key product won approval from the US Food and Drug Administration
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
InvestEngine
InvestEngine
Account and trading fee-free ETF investing
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
